GESALP ✹ AI

Clinical-grade synthetic data – privacy, utility, and trust.

Investing in the future of privacy-safe clinical data innovation

hi & welcome

WELCOME

TO

OUR

ANGEL

INVESTOR

OPPORTUNITY

— 2025

A short introduction
about Gesalp AI

At Gesalp AI, everything began with a simple question asked on a calm dinner night — *"Would you share your health data for research?"*

That one question revealed a universal problem in healthcare:

accessing real patient data is slow, heavily restricted, and full of legal and privacy risks. This inspired me to build a solution where innovation doesn't come at the cost of privacy.

Gesalp AI is a Swiss-based health data initiative (currently in bootstrap stage) focused on generating synthetic health datasets that are as realistic as real data - but without exposing any personal information.

Our vision is to unlock the power of data for research, AI development, and clinical trials, while staying fully compliant with privacy regulations. With synthetic data, hospitals, CROs, and researchers can collaborate faster, safer, and with full trust.

We are now entering a crucial phase:

finalizing the MVP and preparing pilot collaborations with hospitals and research partners across Switzerland and the EU. I'm looking for angel investors and co-founders who believe in building ethical, future-proof data solutions.

Location:

Paris → Moving to Zürich, Switzerland CH

"Real innovation begins when trust meets technology."

— Kogulan Natarajan, Founder & CEO

INDEX

Get in Touch

GESALP AI

Contact Email

info@gesalpai.ch

Registered business address via Les Tricolores*

The Problem We're Solving

Access to real healthcare data is one of the **biggest bottlenecks** in medical innovation. Even world-class AI teams, hospitals, and researchers struggle to get the data they need - securely, quickly, and legally.

Data Access is Slow and Expensive

Clinical and health data is locked behind complex legal, regulatory, and ethical layers. Getting access often takes 6-18 months, making research cycles painfully slow.

Privacy Risks Block Innovation

Even when data is "de-identified," it can often be re-identified. This creates high legal liability for hospitals and startups — and most projects never move forward.

Lack of Scalable Data Infrastructure

Current solutions are not designed for AI. Data is fragmented, inconsistent, and not standardized for fast model training or analysis.

Missed Opportunities

Because of these barriers, thousands of research projects and clinical trials are delayed or never happen, costing billions in lost innovation.

Privacy is not a blocker anymore – it's a feature.

Our Solution — Synthetic Real Data

We make clinical-grade synthetic data accessible, privacy-safe, and ready for AI - in weeks, not years.

Synthetic Data That's Realistic

We generate privacy-preserving synthetic datasets that maintain the statistical accuracy and utility of real patient data - without exposing sensitive information.

Regulatory Peace of Mind

Our synthetic data is fully GDPR & HIPAA compliant by design.
This means hospitals, CROs, and AI startups can innovate without legal risk.

Plug-and-Play Infrastructure

Our platform provides standardized, structured data pipelines that make integration into ML workflows effortless — SaaS or on-prem.

Faster Research and Trials

Access to clean, standardized synthetic health data accelerates model development, clinical trial simulation, and AI validation — cutting project timelines from months to days.

Key Features

&

Differentiators

Our technology is built to meet the strict demands of clinical and health data ecosystems.
We don't just generate synthetic data — we make it regulatory-grade, scalable, and trustworthy.

Clinical-Grade Synthetic Data

Unlike general-purpose generators, our platform produces high-fidelity synthetic health records aligned with clinical coding standards (ICD, SNOMED, LOINC, etc.).

Strong Privacy Guarantees

We implement advanced privacy techniques (e.g., differential privacy, k-anonymity, MIA testing) - ensuring every dataset is provably safe for sharing and compliant with EU regulations.

Dataset Cards & Audit Reports

Every generated dataset comes with a transparency card and audit trail — making it easy to verify provenance, quality, and compliance at a glance.

Flexible Deployment

Gesalp AI runs as a SaaS platform or fully on-premises, giving hospitals and CROs complete control over their data pipelines.

Dataset Cards & Audit Reports

Every generated dataset comes with a transparency card and audit trail — making it easy to verify provenance, quality, and compliance at a glance.

Why Now?

Why is now the right time to invest in Gesalp AI?

Demand for Synthetic Healh Data	Supportive Regulatory Environment	Recent AI Breakthroughs

Healthcare data is the new gold but privacy is the vault.

First-mover advantage in EU/CH market

Explosive demand for privacy-safe data

The demand for privacy-safe health data is growing rapidly — driven by new regulations, the boom in AI-driven clinical research, and the global need for secure data sharing.

Regulatory Tailwinds

- GDPR and Swiss nFADP encourage privacy-first innovation.
- EU EHDS 2025 aims to make secure data sharing and research collaboration easier.

AI & Data Market Convergence

AI models are ready — data is the bottleneck. Synthetic data accelerates R&D and trial simulation without legal risks.

MARKET
GROWTH

Global Synthetic Data Market

$3.7B

$0.49B

2025   2030

CAGR ~41.8%

one of the fastest-growing

markets in health tech.

EU Clinical Trials Market

$32.43B

$23.59B

CAGR ~6.9%

driven by European Health

Data Space (EHDS) and CTR

reforms

2025   2030

MARKET
GROWTH

Business Model

&

Go-to-Market

revenue mix

subscription engine

marketplace

We generate value through a

dual-revenue model

designed for both scalability and
sustainability.

Engine (SaaS & On-Prem)

- Subscription model for hospitals, CROs, and research partners.

- Usage-based pricing linked to dataset size and privacy budget (ε).

- Optional premium privacy audits and support.

Marketplace Revenue

- Hospitals and data owners can monetize synthetic datasets without sharing real data.

- We earn a revenue share per transaction on the marketplace.

Services & Add-ons *(future expansion)*

- Regulatory audits, compliance certifications, and integration support.

- Custom AI/ML pipeline configuration.

go-to-market

strategy

We'll start in

Switzerland and the EU

with pilot projects and trusted healthcare partners.

Early Pilots

Launch with 2-3 Swiss/EU hospitals and CROs to validate technology, compliance, and utility.

Channel Partnerships

Collaborate with EHR integrators, data marketplaces, and compliance firms to scale distribution.

Thought Leadership & Trust

Publish dataset cards, whitepapers, and case studies to position Gesalp AI as the trusted privacy-safe data layer for healthcare innovation.

Funding Ask

&

Use of Funds

Target Raise   €72,000 – €96,000 total

funding asks

We're seeking €6,000 – €8,000 per month over the next 12 months to accelerate our journey from near-MVP to a fully validated product with live pilots and early commercial traction.

This amount ensures lean but focused execution — covering core technology, legal founder support through URSSAF, expert guidance, and pilot programs with hospitals and CROs.

how we'll use the funds

MVP Development & Tech Infrastructure `35%`

- Finalize product engine and dataset card architecture
- Launch privacy stop-gates and reporting pipelines
- Cloud infrastructure, tooling, and security

Compliance & Pilot Programs `20%`

- Privacy & regulatory certifications
- Pilot deployment with hospitals and CROs
- Collect utility and compliance validation metrics

Founder Stipend Modest `20%`

- legal stipend through URSSAF to support full-time founder commitment
- Ensures focus without personal financial strain
- stop-gates and reporting pipelines
- Cloud infrastructure, tooling, and security

Expert & Operational Support `15%`

- Co-working / office expenses
- External legal, regulatory, and product mentors

Go-to-Market & Partnerships `10%`

- Marketing content, investor relations, conferences
- Partnership development and early sales activities

Funding Round Type

Early-stage angel investment

(pre-seed / convertible equity or direct equity)

Why Angel Investors?

Small, focused round

with a clear execution plan

Lean structure

full-time founder, minimal overhead, strong technical base

Early backers

get priority allocation and long-term upside

Transparent reporting

and direct access to product evolution

Positioned in a high-growth

EU/Swiss healthcare data market

Traction

&

Roadmap

Even as a bootstrap project, we've already built a

strong foundation

for rapid progress.

MVP Progress

- Core engine and dataset card architecture are live in near-MVP form.
- Privacy stop-gates and audit workflows are implemented.
- near-MVP link: https://gesalps.vercel.app/en

Market Validation

- Investor interest initiated — first serious discussions in Barcelona
- Conversations with Swiss/EU hospital networks and CRO contacts are ongoing.

Product Differentiation

- DP-powered engine, healthcare-specific focus, on-prem flexibility, and dataset cards give us a clear edge over general synthetic data providers

roadmap

A clear 12-month execution path to move from MVP to paying partners.

- First paying customers
- Foundation for larger seed round

Q3 -2026

- Finalize MVP and conduct internal testing
- Prepare compliance & security workflows

Q4 -2025

- Launch 2-3 live pilots with hospitals/CROs
- Run first privacy audits and dataset card publication

Q1 -2026

- Regulatory validation and marketplace readiness
- Expand pilots → early commercial agreements

Q2 -2026

Competitor

Landscape

Feature / Capability	GESALP AI	MOSTLY AI	MDCLONE	GRETEL	SYNTEGRA
Healthcare-specific focus	✓	✓	✓	✓	✓
Differential Privacy (DP) guarantees	✓	✓	⚠	✓	⚠!
Dataset cards + audit trail	✓	✓	✗	✓	✓
On-prem deployment	✓	✓	✗	✓	✓
EU/Swiss regulatory alignment	✓	✓	⚠	✓	✓
Marketplace-ready architecture	✓	✓	⚠	✗	✗

✓ = strong offering ⚠ = partial/limited ✗ = not supported

- The synthetic data market is heating up — but most solutions are either generic or don't meet healthcare compliance standards.

- This creates a clear strategic gap for Gesalp AI to lead in the EU/Swiss clinical data segment.

Team & Advisors

We're building a lean, world-class team to make privacy-safe healthcare data a reality.

Kogulan Natarajan

Founder & CEO

- 8+ years in data engineering and AI

- Expertise in healthcare data, privacy architectures, and cloud infrastructure

- Previously at Data4Aim | MSc in Data Science & Analytics, EPITA

- Registered under URSSAF (France) for lean, legal early-stage execution

- Currently full-time on Gesalp AI

Planned Key Roles (Roadmap to Team Build-Up)

| Tech Co-Founder / Lead Engineer | Legal & Compliance | GTM & Partnerships |

Advisory Network (in-progress)

- Domain experts in clinical data, privacy, and marketplace strategy
- Targeting early partnerships with legal and compliance experts to support audits, pilots, and regulatory review

Let's build
the future of
privacy-safe
clinical research.

MVP (Near Live)

Get in Touch

Contact Email

info@gesalpai.ch

Business Address

Kogulan Natarajan
Business Domiciliation
6 rue d'Armaillé, 75017
Paris
France

Registered business address via Les Tricolores*

Explore the n/MVP here